MedTrace Logo

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

NCT03006367 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-07-06

No results posted yet for this study

Summary

This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

NFC-1 100 mg

DRUG

NFC-1 200 mg

DRUG

NFC-1 400 mg

DRUG

NFC-1 800 mg

Sponsors & Collaborators

  • Aevi Genomic Medicine, LLC, a Cerecor company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-07
Primary Completion
2017-02-26
Completion
2017-03-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006367 on ClinicalTrials.gov